Natural Product Research
June 2, 2026
Genís Ona, Cristina Llagostera, Oscar Alvarez et al.
Psilocybin, the main psychoactive compound in Psilocybe cubensis mushrooms, has gained considerable attention for its therapeutic potential. Current research focuses only on isolated psilocybin, neglecting the broader pharmacological and cultural use of the whole mushroom. This perspective advocates for an integrative approach that includes standardised P. cubensis extracts within the...
Journal of Psychedelic Studies
March 9, 2026
Genís Ona, Sidsel Marie
Abstract Background and aims Ibogaine, one of the oldest psychedelic alkaloids introduced to Western society and medicine, has a largely overlooked history prior to Howard Lotsof's accidental identification of its anti-addictive properties in the 1960s. This manuscript explores some previously hidden aspects of ibogaine, with a focus on the entangled cultural, colonial, and scientific histories...
Lancet Reg Health Eur
November 20, 2025
Santiago Madero, Oscar Soto-Angona, Genís Ona et al.
9 citations
In this viewpoint, we explore the evolving landscape of psychedelic-assisted therapy in Europe, focusing on clinical, regulatory, and therapeutic developments. While access remains limited, recent initiatives in Switzerland, Germany, and the Czech Republic illustrate growing momentum toward regulated use. We examine the debate surrounding psychedelics as pharmacological agents versus...
Journal of Contextual Behavioral Science
July 1, 2025
Oscar Soto-Angona, Amanda Rodríguez‐Urrutia, Josep Antoni Ramos‐quiroga et al.
1 citation
Altres ajuts: acords transformatius de la UAB
Nature Medicine
June 3, 2025
Chloé Pronovost-Morgan, Kyle T. Greenway, Leor Roseman et al.
26 citations
Psychedelic substances exhibit complex interactions with the 'set and setting' of use, that is, the mental state of the user and the environment in which a psychedelic experience takes place. Despite these contextual variables' known importance, psychedelic research has lacked methodological rigor in reporting extra-pharmacological factors. This study aimed to generate consensus-based...
Neuroscience of Consciousness
2025
Christopher Timmermann, James W. Sanders, David Reydellet et al.
19 citations
5-MeO-DMT is a short-acting psychedelic that is anecdotally reported to induce a radical disruption of the self and a paradoxical quality of aroused, waking awareness that is nevertheless devoid of any specific perceptual contents. Here, we conducted an exploratory observational study of the phenomenological and neuronal effects of this compound. We collected micro-phenomenological interviews,...
Frontiers in Psychiatry
2025
Jonathan David, José Carlos Bouso, Maja Kohek et al.
correction
1. In the published article, there was an error. The error was regarding the average number of ayahuasca uses in the ayahuasca group in Study 1. A correction has been made to the Results section in lines 387-390. This sentence previously stated:Briefly, on average, our study participants have used ayahuasca (mean = 69.4 ± 98.7), 6.4 times more than psilocybin (mean = 10.7 ± 15.4, U = 1378, p <...
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
August 1, 2024
Oscar Soto-Angona, Adriana Fortea, Lydia Fortea et al.
7 citations
Seizures are a concerning adverse event frequently associated with the use of psychedelics, and hence, studies involving these substances tend to exclude patients with past history of epilepsy. This is especially relevant because epileptic seizures are markedly increased in the population suffering from mental disorders, and psychedelic assisted therapy is being researched as a promising...
International Clinical Psychopharmacology
June 27, 2024
Alberto Sainz-Cort, Marta Martín-Islas, Daniel Jiménez‐garrido et al.
1 citation
OBJECTIVE: While social cognition is shown to be impaired in several mental disorders, the effects of cannabis on social cognition are still not clear. Past studies have used the multifaceted empathy test (MET) to study social cognition. This study aims to test the validity of the MET Spanish version and to evaluate the effects of cannabis use on social cognition. METHODS: In total 116...
Translational Psychiatry
January 19, 2024
Judit Biosca-Brull, Genís Ona, Lineth Alarcón-franco et al.
5 citations
Ibogaine (IBO) is an atypical psychedelic with a complex mechanism of action. To date, the mechanisms that may underlie its anti-addictive effects are still not defined. This study aims to identify changes in gene expression induced by a single oral dose of IBO in the cortex of mice by means of a transcriptomic analysis for the first time. Our results showed significant alterations in gene...
Frontiers in Psychiatry
December 19, 2023
Jonathan David, José Carlos Bouso, Maja Kohek et al.
14 citations
Introduction Despite an emerging understanding regarding the pivotal mechanistic role of subjective experiences that unfold during acute psychedelic states, very little has been done in the direction of better characterizing such experiences and determining their long-term impact. The present paper utilizes two cross-sectional studies for spotlighting – for the first time in the literature –...
Journal of psychopharmacology (Oxford, England)
December 1, 2023
Genís Ona, Ingrid Reverte, Giordano N. Rossi et al.
20 citations
There is a growing interest in studying ibogaine (IBO) as a potential treatment for substance use disorders (SUDs). However, its clinical use has been hindered for mainly two reasons: First, the lack of randomized, controlled studies informing about its safety and efficacy. And second, IBO's mechanisms of action remain obscure. It has been challenging to elucidate a predominant mechanism of...
Revista de Antropología Social
November 20, 2023
Maja Kohek, José Carlos Bouso, Genís Ona
3 citations
Este artículo presenta un estudio de caso de una mujer que emigró de la selva brasileña a Barcelona hace diecisiete años, y su camino para convertirse en una curandera que trabaja con ayahuasca, kambó (veneno de rana) y sananga (colirio herbal). Se discuten las nociones de autenticidad, communitas y autoatención. Sostenemos que el chamanismo, la religión y la salud son procesos fluidos y...
Quaderns de l Institut Català d Antropologia
October 24, 2023
Genís Ona
2 citations
Actualmente estamos asistiendo a un renovado interés académico por drogas alucinógenas como la psilocibina o la ayahuasca. El uso clínico de alucinógenos se ha acompañado pormodelos psicoterapéuticos con los cuales se direccionan sus efectos subjetivos. El enfoqueclínico desarrollado en Brasil es especialmente interesante, ya que no cuenta con orientacionespsicoterapéuticas o técnicas de...
Scientific Reports
September 11, 2023
José Carlos Bouso, Dóra Révész, Genís Ona et al.
9 citations
The COVID-19 pandemic has had a devastating impact on the health and wellbeing of the global population. This paper presents the results of a longitudinal transcultural study that was begun at the peak of the pandemic (in April, 2020). An online survey was used to collect data from English-, Spanish-, and Portuguese-speaking participants. The survey collected information about...
Culture, Medicine and Psychiatry
June 1, 2023
José Carlos Bouso, Genís Ona, Maja Kohek et al.
8 citations
Hallucinations are currently associated almost exclusively with psychopathological states. While it is evident that hallucinations can indicate psychopathology or neurological disorders, we should remember that hallucinations also commonly occur in people without any signs of psychopathology. A similar case occurs in the case of hallucinogenic drugs, which have been long associated with...
Natural Product Research
May 1, 2023
Genís Ona, Maja Kohek, José Carlos Bouso
2 citations
Can the emerging field of psychedelic research benefit from natural product research? We believe it can. In this manuscript we delineate certain topics of research with hallucinogens that directly connect with research on natural products in general.
Psychoactives
March 20, 2023
Guilherme Henrique de Morais Santos, Lucas Silva Rodrigues, Juliana Mendes Rocha et al.
6 citations
Background: Ayahuasca is a serotoninergic hallucinogen that plays a central role in the Amazonian traditional medicine. Its psychoactive effects are associated with the presence of N,N-dimethyltryptamine (DMT), and monoamine oxidase inhibitors (MAO-A). Advances in neuroimaging investigations have provided insight into ayahuasca’s neurobiological mechanisms of action. Methods: Selecting only...
Drug and Alcohol Review
February 1, 2023
Borja J Rodríguez-cano, Maja Kohek, Genís Ona et al.
17 citations
Ibogaine is one of the alkaloids naturally found in plants such as Tabernanthe iboga, which has been traditionally used by members of the Bwiti culture. Since the discovery of its anti-addictive properties by Howard S. Lotsof in 1962, ibogaine has been used experimentally to treat substance use disorders (SUD), especially those involving opioids. We aim to provide a detailed understanding of...
Transcultural Psychiatry
October 1, 2022
Genís Ona, Ali Berrada, José Carlos Bouso
28 citations
The Global Mental Health (GMH) movement aims to provide urgently needed treatment to those with mental illness, especially in low- and middle-income countries. Due to the complexity of providing mental health services to people from various cultures, there is much debate among GMH advocates regarding the best way to proceed. While biomedical interventions offer some degree of help,...
Psychoactives
September 2, 2022
Genís Ona, Dóra Révész, Maja Kohek et al.
9 citations
The COVID-19 pandemic has made evident the need to develop effective strategies to cushion the psychological consequences of social catastrophes. Preliminary evidence suggests that the use of hallucinogens is a protective factor that mitigates against such stressors. However, the underlying mechanisms must be further explored. This study specifically focused on the potential role of coping...
Psychopharmacology
June 1, 2022
Genís Ona, Juliana Mendes Rocha, José Carlos Bouso et al.
41 citations
Ibogaine is the main alkaloid of the African shrub Tabernanthe iboga. It produces hallucinogenic and psychostimulant effects, but it is currently known for the anti-addictive properties. Despite the potential therapeutic effects, several cases of fatalities and serious adverse events related to ibogaine/noribogaine use can be found in the literature. Most studies consist in case reports or were...
Journal of Psychoactive Drugs
May 28, 2022
Maja Kohek, Genís Ona, Michiel van Elk et al.
25 citations
Ayahuasca is a plant decoction in traditional Amazonian medicine. Its ritual use has been internationalized, leading to policy challenges that countries should address. This study evaluates the impact of regular ayahuasca ceremony participation on health by assessing the health status of 377 participants in ayahuasca ceremonies in the Netherlands using validated health indicators. A...
Human Psychopharmacology Clinical and Experimental
February 2, 2022
Rafael G. Dos Santos, Juliana Mendes Rocha, Giordano Novak Rossi et al.
20 citations
Abstract Objective To assess endocannabinoid (anandamide, AEA; 2‐arachidonoylglycerol, 2‐AG) plasma levels in healthy volunteers and in volunteers with social anxiety disorder (SAD) after a single oral dose of ayahuasca or placebo. Methods Post hoc analysis of endocannabinoid plasma levels (baseline, 90 and 240 min after drug intake) from two parallel‐group, randomized, placebo‐controlled...
The International Journal of Neuropsychopharmacology
January 12, 2022
Genís Ona, Frederic Sampedro, Sergio Romero et al.
17 citations
The mechanisms through which kappa opioid receptor (KOR) agonists induce psychotomimetic effects are largely unknown, although the modulation of this receptor has attracted attention for its clinical use. In this work, we characterize the neuropharmacological effects of salvinorin-A, a highly selective KOR agonist. Changes in multimodal electroencephalography, single-photon emission computed...